Linagliptin Viatris

Linagliptin, the active ingredient in Linagliptin Viatris, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adults.

GNH USA supplies Linagliptin Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus.

- Type 2 diabetes mellitus (monotherapy): lowers blood glucose and HbA1c as a single oral agent. - Type 2 diabetes mellitus (combination therapy): enhances glycemic control when added to metformin or other antidiabetic agents. - Type 2 diabetes mellitus (adjunct to lifestyle): supports diet and exercise interventions to improve overall glucose management.

Linagliptin may cause adverse reactions, which are categorized by frequency.

Common Side Effects: - Nausea - Headache - Nasopharyngitis - Dizziness - Arthralgia - Mild hypoglycaemia (when combined with insulin or sulfonylureas)

Serious or Rare Side Effects: - Pancreatitis - Severe allergic reactions such as angioedema or anaphylaxis - Liver injury (hepatitis, elevated transaminases) - Bullous pemphigoid skin disorder - Severe hypoglycaemia (especially with insulin therapy) - Acute renal impairment in susceptible patients

When prescribing Linagliptin, clinicians should consider the following precautions.

- Renal function: no dose adjustment is required, but monitor patients with severe renal impairment. - Hepatic impairment: use with caution in moderate liver disease. - Cardiovascular risk: assess patients with a history of heart failure. - Concomitant hypoglycaemic agents: adjust dose of sulfonylureas or insulin to avoid hypoglycaemia. - Pregnancy and lactation: avoid use due to insufficient safety data. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Linagliptin can interact with other medicines; notable interactions are grouped by clinical relevance.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce linagliptin exposure. - Insulin or sulfonylureas: increased risk of hypoglycaemia.

Moderate Interactions (Monitor Closely): - Diuretics (e.g., thiazides): may enhance hypoglycaemic effect. - ACE inhibitors or ARBs: potential additive blood‑pressure effects. - Anticoagulants (e.g., warfarin): monitor INR as changes have been reported. - Oral contraceptives: may slightly increase linagliptin levels.